Peregrine Redeemed: Phase II Bavi Discrepancies Minimal
By Catherine Shaffer
Monday, January 7, 2013
Peregrine Pharmaceuticals Inc.'s internal review of vial coding discrepancies from a Phase II trial of bavituximab in non-small-cell lung cancer (NSCLC) showed that the errors were isolated to placebo and 1-mg/kg treatment arms, leaving the 3-mg/kg treatment arm unaffected.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.